Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report)’s share price traded up 7.1% during mid-day trading on Monday . The company traded as high as $45.01 and last traded at $44.89. 216,494 shares changed hands during trading, a decline of 73% from the average session volume of 788,317 shares. The stock had previously closed at $41.92.
Analyst Ratings Changes
A number of brokerages have commented on GPCR. Morgan Stanley initiated coverage on shares of Structure Therapeutics in a research note on Monday. They issued an “overweight” rating and a $118.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday. BMO Capital Markets upped their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. Finally, JMP Securities cut their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has an average rating of “Buy” and an average price target of $88.33.
Get Our Latest Analysis on GPCR
Structure Therapeutics Price Performance
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. As a group, equities research analysts predict that Structure Therapeutics Inc. will post -0.86 earnings per share for the current year.
Institutional Trading of Structure Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of GPCR. Sandia Investment Management LP purchased a new position in Structure Therapeutics during the 2nd quarter worth $39,000. Quarry LP bought a new position in shares of Structure Therapeutics during the 2nd quarter worth $79,000. Sectoral Asset Management Inc. purchased a new position in shares of Structure Therapeutics during the fourth quarter valued at $139,000. ADAR1 Capital Management LLC bought a new stake in shares of Structure Therapeutics in the fourth quarter valued at about $163,000. Finally, Sei Investments Co. bought a new stake in shares of Structure Therapeutics in the second quarter valued at about $212,000. Institutional investors own 91.78% of the company’s stock.
About Structure Therapeutics
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Stories
- Five stocks we like better than Structure Therapeutics
- How to buy stock: A step-by-step guide for beginners
- The Average 401k Balance by Age Explained
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What Do S&P 500 Stocks Tell Investors About the Market?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.